Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis.
Identifieur interne : 000A26 ( Main/Exploration ); précédent : 000A25; suivant : 000A27Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis.
Auteurs : Sobhana Thangaraju [États-Unis] ; Jagbir Gill ; Allissa Wright ; Jianghu Dong ; Caren Rose ; John GillSource :
- Transplantation [ 1534-6080 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Ajustement du risque (MeSH), Antigènes HLA (immunologie), Antiviraux (usage thérapeutique), Charge virale (MeSH), Donneurs de tissus (MeSH), Enregistrements (MeSH), Estimation de Kaplan-Meier (MeSH), Facteurs de risque (MeSH), Facteurs sexuels (MeSH), Facteurs temps (MeSH), Facteurs âges (MeSH), Femelle (MeSH), Histocompatibilité (MeSH), Humains (MeSH), Immunosuppresseurs (effets indésirables), Infections opportunistes (diagnostic), Infections opportunistes (immunologie), Infections opportunistes (mortalité), Infections opportunistes (traitement médicamenteux), Infections opportunistes (virologie), Infections à polyomavirus (diagnostic), Infections à polyomavirus (immunologie), Infections à polyomavirus (mortalité), Infections à polyomavirus (traitement médicamenteux), Infections à polyomavirus (virologie), Infections à virus oncogènes (diagnostic), Infections à virus oncogènes (immunologie), Infections à virus oncogènes (mortalité), Infections à virus oncogènes (traitement médicamenteux), Infections à virus oncogènes (virologie), Jeune adulte (MeSH), Maladies du rein (diagnostic), Maladies du rein (immunologie), Maladies du rein (traitement médicamenteux), Maladies du rein (virologie), Modèles des risques proportionnels (MeSH), Mâle (MeSH), Sujet immunodéprimé (MeSH), Transplantation rénale (effets indésirables), Transplantation rénale (mortalité), Transplantation rénale (méthodes), Virus BK (effets des médicaments et des substances chimiques), Virus BK (pathogénicité), Échec thérapeutique (MeSH).
- MESH :
- diagnostic : Infections opportunistes, Infections à polyomavirus, Infections à virus oncogènes, Maladies du rein.
- effets des médicaments et des substances chimiques : Virus BK.
- effets indésirables : Immunosuppresseurs, Transplantation rénale.
- immunologie : Antigènes HLA, Infections opportunistes, Infections à polyomavirus, Infections à virus oncogènes, Maladies du rein.
- mortalité : Infections opportunistes, Infections à polyomavirus, Infections à virus oncogènes, Transplantation rénale.
- méthodes : Transplantation rénale.
- pathogénicité : Virus BK.
- traitement médicamenteux : Infections opportunistes, Infections à polyomavirus, Infections à virus oncogènes, Maladies du rein.
- usage thérapeutique : Antiviraux.
- virologie : Infections opportunistes, Infections à polyomavirus, Infections à virus oncogènes, Maladies du rein.
- Adolescent, Adulte, Adulte d'âge moyen, Ajustement du risque, Charge virale, Donneurs de tissus, Enregistrements, Estimation de Kaplan-Meier, Facteurs de risque, Facteurs sexuels, Facteurs temps, Facteurs âges, Femelle, Histocompatibilité, Humains, Jeune adulte, Modèles des risques proportionnels, Mâle, Sujet immunodéprimé, Échec thérapeutique.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Age Factors (MeSH), Antiviral Agents (therapeutic use), BK Virus (drug effects), BK Virus (pathogenicity), Female (MeSH), HLA Antigens (immunology), Histocompatibility (MeSH), Humans (MeSH), Immunocompromised Host (MeSH), Immunosuppressive Agents (adverse effects), Kaplan-Meier Estimate (MeSH), Kidney Diseases (diagnosis), Kidney Diseases (drug therapy), Kidney Diseases (immunology), Kidney Diseases (virology), Kidney Transplantation (adverse effects), Kidney Transplantation (methods), Kidney Transplantation (mortality), Male (MeSH), Middle Aged (MeSH), Opportunistic Infections (diagnosis), Opportunistic Infections (drug therapy), Opportunistic Infections (immunology), Opportunistic Infections (mortality), Opportunistic Infections (virology), Polyomavirus Infections (diagnosis), Polyomavirus Infections (drug therapy), Polyomavirus Infections (immunology), Polyomavirus Infections (mortality), Polyomavirus Infections (virology), Proportional Hazards Models (MeSH), Registries (MeSH), Risk Adjustment (MeSH), Risk Factors (MeSH), Sex Factors (MeSH), Time Factors (MeSH), Tissue Donors (MeSH), Treatment Failure (MeSH), Tumor Virus Infections (diagnosis), Tumor Virus Infections (drug therapy), Tumor Virus Infections (immunology), Tumor Virus Infections (mortality), Tumor Virus Infections (virology), Viral Load (MeSH), Young Adult (MeSH).
- MESH :
- chemical , adverse effects : Immunosuppressive Agents.
- chemical , immunology : HLA Antigens.
- chemical , therapeutic use : Antiviral Agents.
- adverse effects : Kidney Transplantation.
- diagnosis : Kidney Diseases, Opportunistic Infections, Polyomavirus Infections, Tumor Virus Infections.
- drug effects : BK Virus.
- drug therapy : Kidney Diseases, Opportunistic Infections, Polyomavirus Infections, Tumor Virus Infections.
- immunology : Kidney Diseases, Opportunistic Infections, Polyomavirus Infections, Tumor Virus Infections.
- methods : Kidney Transplantation.
- mortality : Kidney Transplantation, Opportunistic Infections, Polyomavirus Infections, Tumor Virus Infections.
- pathogenicity : BK Virus.
- virology : Kidney Diseases, Opportunistic Infections, Polyomavirus Infections, Tumor Virus Infections.
- Adolescent, Adult, Age Factors, Female, Histocompatibility, Humans, Immunocompromised Host, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Registries, Risk Adjustment, Risk Factors, Sex Factors, Time Factors, Tissue Donors, Treatment Failure, Viral Load, Young Adult.
Abstract
BACKGROUND
Identification of risk factors for BK polyoma virus (BKPyV) without confounding by donor factors and era effects in paired analysis may inform strategies to prevent BKPyV.
METHODS
In this analysis of 21,575 mate kidney pairs in the Scientific Registry of Transplant Recipients between 2004 and 2010, the presence of a treatment code for BKPyV virus in follow-up forms was used to identify pairs in which 1 of 2 mate kidneys was treated (discordant treatment) or both mate kidneys were treated (concordant treatment).
RESULTS
Among 1975 discordant pairs, younger than 18 years or 60 years or older, male sex, HLA mismatch or 4 greater, acute rejection, and depleting antibody induction had a higher odds of treatment, whereas diabetes and sirolimus had a lower odds of treatment, and treatment was associated with a higher risk of allograft failure (hazards ratio, 2.01; 95% confidence interval, 1.63-2.48). The rate of concordant treatment (0.81%) was 2.8 times higher than expected. Concordant treatment was associated with nonwhite donor ethnicity, donation after circulatory death, transplantation after 2008, and transplantation of mate kidneys in the same center.
CONCLUSIONS
This analysis of kidneys from the same donor in which only 1 transplant was treated for BKPyV identifies specific risk factors (age <18 or ≥ 60 years, male sex, depleting antibody, HLA mismatch ≥ 4) for BKPyV and provides an estimate of the BKPyV-associated risk of allograft failure (hazards ratio = 2.01) without confounding by donor factors or era effects. The higher than expected rate of concordant treatment suggests the importance of donor factors in BKPyV pathogenesis and warrants further study.
DOI: 10.1097/TP.0000000000000890
PubMed: 27003098
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis.</title><author><name sortKey="Thangaraju, Sobhana" sort="Thangaraju, Sobhana" uniqKey="Thangaraju S" first="Sobhana" last="Thangaraju">Sobhana Thangaraju</name><affiliation wicri:level="2"><nlm:affiliation>1 Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.2 Center for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada.3 Division of Infectious Disease, University of British Columbia, Vancouver, British Columbia, Canada.4 Tufts-New England Medical Center, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>1 Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.2 Center for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada.3 Division of Infectious Disease, University of British Columbia, Vancouver, British Columbia, Canada.4 Tufts-New England Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Gill, Jagbir" sort="Gill, Jagbir" uniqKey="Gill J" first="Jagbir" last="Gill">Jagbir Gill</name></author><author><name sortKey="Wright, Allissa" sort="Wright, Allissa" uniqKey="Wright A" first="Allissa" last="Wright">Allissa Wright</name></author><author><name sortKey="Dong, Jianghu" sort="Dong, Jianghu" uniqKey="Dong J" first="Jianghu" last="Dong">Jianghu Dong</name></author><author><name sortKey="Rose, Caren" sort="Rose, Caren" uniqKey="Rose C" first="Caren" last="Rose">Caren Rose</name></author><author><name sortKey="Gill, John" sort="Gill, John" uniqKey="Gill J" first="John" last="Gill">John Gill</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27003098</idno><idno type="pmid">27003098</idno><idno type="doi">10.1097/TP.0000000000000890</idno><idno type="wicri:Area/Main/Corpus">000A76</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A76</idno><idno type="wicri:Area/Main/Curation">000A76</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A76</idno><idno type="wicri:Area/Main/Exploration">000A76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis.</title><author><name sortKey="Thangaraju, Sobhana" sort="Thangaraju, Sobhana" uniqKey="Thangaraju S" first="Sobhana" last="Thangaraju">Sobhana Thangaraju</name><affiliation wicri:level="2"><nlm:affiliation>1 Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.2 Center for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada.3 Division of Infectious Disease, University of British Columbia, Vancouver, British Columbia, Canada.4 Tufts-New England Medical Center, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>1 Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.2 Center for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada.3 Division of Infectious Disease, University of British Columbia, Vancouver, British Columbia, Canada.4 Tufts-New England Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Gill, Jagbir" sort="Gill, Jagbir" uniqKey="Gill J" first="Jagbir" last="Gill">Jagbir Gill</name></author><author><name sortKey="Wright, Allissa" sort="Wright, Allissa" uniqKey="Wright A" first="Allissa" last="Wright">Allissa Wright</name></author><author><name sortKey="Dong, Jianghu" sort="Dong, Jianghu" uniqKey="Dong J" first="Jianghu" last="Dong">Jianghu Dong</name></author><author><name sortKey="Rose, Caren" sort="Rose, Caren" uniqKey="Rose C" first="Caren" last="Rose">Caren Rose</name></author><author><name sortKey="Gill, John" sort="Gill, John" uniqKey="Gill J" first="John" last="Gill">John Gill</name></author></analytic><series><title level="j">Transplantation</title><idno type="eISSN">1534-6080</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Age Factors (MeSH)</term><term>Antiviral Agents (therapeutic use)</term><term>BK Virus (drug effects)</term><term>BK Virus (pathogenicity)</term><term>Female (MeSH)</term><term>HLA Antigens (immunology)</term><term>Histocompatibility (MeSH)</term><term>Humans (MeSH)</term><term>Immunocompromised Host (MeSH)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Kaplan-Meier Estimate (MeSH)</term><term>Kidney Diseases (diagnosis)</term><term>Kidney Diseases (drug therapy)</term><term>Kidney Diseases (immunology)</term><term>Kidney Diseases (virology)</term><term>Kidney Transplantation (adverse effects)</term><term>Kidney Transplantation (methods)</term><term>Kidney Transplantation (mortality)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Opportunistic Infections (diagnosis)</term><term>Opportunistic Infections (drug therapy)</term><term>Opportunistic Infections (immunology)</term><term>Opportunistic Infections (mortality)</term><term>Opportunistic Infections (virology)</term><term>Polyomavirus Infections (diagnosis)</term><term>Polyomavirus Infections (drug therapy)</term><term>Polyomavirus Infections (immunology)</term><term>Polyomavirus Infections (mortality)</term><term>Polyomavirus Infections (virology)</term><term>Proportional Hazards Models (MeSH)</term><term>Registries (MeSH)</term><term>Risk Adjustment (MeSH)</term><term>Risk Factors (MeSH)</term><term>Sex Factors (MeSH)</term><term>Time Factors (MeSH)</term><term>Tissue Donors (MeSH)</term><term>Treatment Failure (MeSH)</term><term>Tumor Virus Infections (diagnosis)</term><term>Tumor Virus Infections (drug therapy)</term><term>Tumor Virus Infections (immunology)</term><term>Tumor Virus Infections (mortality)</term><term>Tumor Virus Infections (virology)</term><term>Viral Load (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Ajustement du risque (MeSH)</term><term>Antigènes HLA (immunologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Charge virale (MeSH)</term><term>Donneurs de tissus (MeSH)</term><term>Enregistrements (MeSH)</term><term>Estimation de Kaplan-Meier (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Facteurs sexuels (MeSH)</term><term>Facteurs temps (MeSH)</term><term>Facteurs âges (MeSH)</term><term>Femelle (MeSH)</term><term>Histocompatibilité (MeSH)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (effets indésirables)</term><term>Infections opportunistes (diagnostic)</term><term>Infections opportunistes (immunologie)</term><term>Infections opportunistes (mortalité)</term><term>Infections opportunistes (traitement médicamenteux)</term><term>Infections opportunistes (virologie)</term><term>Infections à polyomavirus (diagnostic)</term><term>Infections à polyomavirus (immunologie)</term><term>Infections à polyomavirus (mortalité)</term><term>Infections à polyomavirus (traitement médicamenteux)</term><term>Infections à polyomavirus (virologie)</term><term>Infections à virus oncogènes (diagnostic)</term><term>Infections à virus oncogènes (immunologie)</term><term>Infections à virus oncogènes (mortalité)</term><term>Infections à virus oncogènes (traitement médicamenteux)</term><term>Infections à virus oncogènes (virologie)</term><term>Jeune adulte (MeSH)</term><term>Maladies du rein (diagnostic)</term><term>Maladies du rein (immunologie)</term><term>Maladies du rein (traitement médicamenteux)</term><term>Maladies du rein (virologie)</term><term>Modèles des risques proportionnels (MeSH)</term><term>Mâle (MeSH)</term><term>Sujet immunodéprimé (MeSH)</term><term>Transplantation rénale (effets indésirables)</term><term>Transplantation rénale (mortalité)</term><term>Transplantation rénale (méthodes)</term><term>Virus BK (effets des médicaments et des substances chimiques)</term><term>Virus BK (pathogénicité)</term><term>Échec thérapeutique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HLA Antigens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Kidney Diseases</term><term>Opportunistic Infections</term><term>Polyomavirus Infections</term><term>Tumor Virus Infections</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections opportunistes</term><term>Infections à polyomavirus</term><term>Infections à virus oncogènes</term><term>Maladies du rein</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>BK Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Kidney Diseases</term><term>Opportunistic Infections</term><term>Polyomavirus Infections</term><term>Tumor Virus Infections</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Virus BK</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Immunosuppresseurs</term><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes HLA</term><term>Infections opportunistes</term><term>Infections à polyomavirus</term><term>Infections à virus oncogènes</term><term>Maladies du rein</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Kidney Diseases</term><term>Opportunistic Infections</term><term>Polyomavirus Infections</term><term>Tumor Virus Infections</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Kidney Transplantation</term><term>Opportunistic Infections</term><term>Polyomavirus Infections</term><term>Tumor Virus Infections</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections opportunistes</term><term>Infections à polyomavirus</term><term>Infections à virus oncogènes</term><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>BK Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus BK</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections opportunistes</term><term>Infections à polyomavirus</term><term>Infections à virus oncogènes</term><term>Maladies du rein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections opportunistes</term><term>Infections à polyomavirus</term><term>Infections à virus oncogènes</term><term>Maladies du rein</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Kidney Diseases</term><term>Opportunistic Infections</term><term>Polyomavirus Infections</term><term>Tumor Virus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Female</term><term>Histocompatibility</term><term>Humans</term><term>Immunocompromised Host</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Registries</term><term>Risk Adjustment</term><term>Risk Factors</term><term>Sex Factors</term><term>Time Factors</term><term>Tissue Donors</term><term>Treatment Failure</term><term>Viral Load</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Ajustement du risque</term><term>Charge virale</term><term>Donneurs de tissus</term><term>Enregistrements</term><term>Estimation de Kaplan-Meier</term><term>Facteurs de risque</term><term>Facteurs sexuels</term><term>Facteurs temps</term><term>Facteurs âges</term><term>Femelle</term><term>Histocompatibilité</term><term>Humains</term><term>Jeune adulte</term><term>Modèles des risques proportionnels</term><term>Mâle</term><term>Sujet immunodéprimé</term><term>Échec thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Identification of risk factors for BK polyoma virus (BKPyV) without confounding by donor factors and era effects in paired analysis may inform strategies to prevent BKPyV.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>In this analysis of 21,575 mate kidney pairs in the Scientific Registry of Transplant Recipients between 2004 and 2010, the presence of a treatment code for BKPyV virus in follow-up forms was used to identify pairs in which 1 of 2 mate kidneys was treated (discordant treatment) or both mate kidneys were treated (concordant treatment).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Among 1975 discordant pairs, younger than 18 years or 60 years or older, male sex, HLA mismatch or 4 greater, acute rejection, and depleting antibody induction had a higher odds of treatment, whereas diabetes and sirolimus had a lower odds of treatment, and treatment was associated with a higher risk of allograft failure (hazards ratio, 2.01; 95% confidence interval, 1.63-2.48). The rate of concordant treatment (0.81%) was 2.8 times higher than expected. Concordant treatment was associated with nonwhite donor ethnicity, donation after circulatory death, transplantation after 2008, and transplantation of mate kidneys in the same center.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>This analysis of kidneys from the same donor in which only 1 transplant was treated for BKPyV identifies specific risk factors (age <18 or ≥ 60 years, male sex, depleting antibody, HLA mismatch ≥ 4) for BKPyV and provides an estimate of the BKPyV-associated risk of allograft failure (hazards ratio = 2.01) without confounding by donor factors or era effects. The higher than expected rate of concordant treatment suggests the importance of donor factors in BKPyV pathogenesis and warrants further study.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27003098</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2016</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1534-6080</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Transplantation</Title><ISOAbbreviation>Transplantation</ISOAbbreviation></Journal><ArticleTitle>Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis.</ArticleTitle><Pagination><MedlinePgn>854-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TP.0000000000000890</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Identification of risk factors for BK polyoma virus (BKPyV) without confounding by donor factors and era effects in paired analysis may inform strategies to prevent BKPyV.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this analysis of 21,575 mate kidney pairs in the Scientific Registry of Transplant Recipients between 2004 and 2010, the presence of a treatment code for BKPyV virus in follow-up forms was used to identify pairs in which 1 of 2 mate kidneys was treated (discordant treatment) or both mate kidneys were treated (concordant treatment).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1975 discordant pairs, younger than 18 years or 60 years or older, male sex, HLA mismatch or 4 greater, acute rejection, and depleting antibody induction had a higher odds of treatment, whereas diabetes and sirolimus had a lower odds of treatment, and treatment was associated with a higher risk of allograft failure (hazards ratio, 2.01; 95% confidence interval, 1.63-2.48). The rate of concordant treatment (0.81%) was 2.8 times higher than expected. Concordant treatment was associated with nonwhite donor ethnicity, donation after circulatory death, transplantation after 2008, and transplantation of mate kidneys in the same center.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This analysis of kidneys from the same donor in which only 1 transplant was treated for BKPyV identifies specific risk factors (age <18 or ≥ 60 years, male sex, depleting antibody, HLA mismatch ≥ 4) for BKPyV and provides an estimate of the BKPyV-associated risk of allograft failure (hazards ratio = 2.01) without confounding by donor factors or era effects. The higher than expected rate of concordant treatment suggests the importance of donor factors in BKPyV pathogenesis and warrants further study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thangaraju</LastName><ForeName>Sobhana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.2 Center for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada.3 Division of Infectious Disease, University of British Columbia, Vancouver, British Columbia, Canada.4 Tufts-New England Medical Center, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Jagbir</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Allissa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Jianghu</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Caren</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplantation</MedlineTA><NlmUniqueID>0132144</NlmUniqueID><ISSNLinking>0041-1337</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001739" MajorTopicYN="N">BK Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006648" MajorTopicYN="N">Histocompatibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009894" MajorTopicYN="N">Opportunistic Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027601" MajorTopicYN="N">Polyomavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020379" MajorTopicYN="N">Risk Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014019" MajorTopicYN="N">Tissue Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014412" MajorTopicYN="N">Tumor Virus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27003098</ArticleId><ArticleId IdType="doi">10.1097/TP.0000000000000890</ArticleId><ArticleId IdType="pii">00007890-201604000-00027</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><noCountry><name sortKey="Dong, Jianghu" sort="Dong, Jianghu" uniqKey="Dong J" first="Jianghu" last="Dong">Jianghu Dong</name><name sortKey="Gill, Jagbir" sort="Gill, Jagbir" uniqKey="Gill J" first="Jagbir" last="Gill">Jagbir Gill</name><name sortKey="Gill, John" sort="Gill, John" uniqKey="Gill J" first="John" last="Gill">John Gill</name><name sortKey="Rose, Caren" sort="Rose, Caren" uniqKey="Rose C" first="Caren" last="Rose">Caren Rose</name><name sortKey="Wright, Allissa" sort="Wright, Allissa" uniqKey="Wright A" first="Allissa" last="Wright">Allissa Wright</name></noCountry><country name="États-Unis"><region name="Massachusetts"><name sortKey="Thangaraju, Sobhana" sort="Thangaraju, Sobhana" uniqKey="Thangaraju S" first="Sobhana" last="Thangaraju">Sobhana Thangaraju</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27003098
|texte= Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27003098" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |